Your browser doesn't support javascript.
loading
Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.
Zhou, Wei; Fang, Peng; Yu, Dongan; Ren, Hongyuan; You, Meng; Yin, Long; Mei, Fei; Zhu, Huikai; Wang, Zhenzhen; Xu, Hui; Cao, Yuxia; Sun, Xiaowei; Xu, Xiaohong; Bi, Jianjun; Wang, Jin; Ma, Lanping; Wang, Xin; Chen, Lin; Zhang, Yongliang; Cen, Xiaowei; Zhu, Xi; Lou, Liguang; Liu, Datao; Tan, Xiaoding; Yang, Jinliang; Meng, Tao; Shen, Jingkang.
Afiliación
  • Zhou W; Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
  • Fang P; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
  • Yu D; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Ren H; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
  • You M; Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd., Taizhou, China.
  • Yin L; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
  • Mei F; Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd., Taizhou, China.
  • Zhu H; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
  • Wang Z; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
  • Xu H; Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd., Taizhou, China.
  • Cao Y; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
  • Sun X; Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd., Taizhou, China.
  • Xu X; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
  • Bi J; Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd., Taizhou, China.
  • Wang J; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
  • Ma L; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
  • Wang X; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
  • Chen L; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
  • Zhang Y; Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd., Taizhou, China.
  • Cen X; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
  • Zhu X; Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd., Taizhou, China.
  • Lou L; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
  • Liu D; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
  • Tan X; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
  • Yang J; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Meng T; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Shen J; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Mol Cancer Ther ; 22(8): 913-925, 2023 08 01.
Article en En | MEDLINE | ID: mdl-37196158
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoconjugados / Neoplasias Límite: Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoconjugados / Neoplasias Límite: Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos